CTIC - CTI BioPharma Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 553.34M
Enterprise Value 311.41M
Trailing P/E N/A
Forward P/E 1-0.94
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)3.36
Price/Book (mrq)1.31
Enterprise Value/Revenue 30.72
Enterprise Value/EBITDA 6-0.34

Trading Information

Stock Price History

Beta (3Y Monthly) 2.16
52-Week Change 3-54.59%
S&P500 52-Week Change 32.99%
52 Week High 32.3000
52 Week Low 30.6000
50-Day Moving Average 30.7368
200-Day Moving Average 30.8606

Share Statistics

Avg Vol (3 month) 3242.4k
Avg Vol (10 day) 3135.51k
Shares Outstanding 557.98M
Float 35.71M
% Held by Insiders 10.76%
% Held by Institutions 161.04%
Shares Short (Aug 15, 2019) 4280.89k
Short Ratio (Aug 15, 2019) 41.79
Short % of Float (Aug 15, 2019) 40.58%
Short % of Shares Outstanding (Aug 15, 2019) 40.48%
Shares Short (prior month Jul 15, 2019) 4515.29k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 210/1
Last Split Date 3Jan 3, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -225.01%
Operating Margin (ttm)-218.00%

Management Effectiveness

Return on Assets (ttm)-25.64%
Return on Equity (ttm)-72.52%

Income Statement

Revenue (ttm)15.89M
Revenue Per Share (ttm)0.27
Quarterly Revenue Growth (yoy)-32.10%
Gross Profit (ttm)25.41M
EBITDA -34.07M
Net Income Avi to Common (ttm)-35.75M
Diluted EPS (ttm)-0.6160
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)53.66M
Total Cash Per Share (mrq)0.93
Total Debt (mrq)17.5M
Total Debt/Equity (mrq)50.02
Current Ratio (mrq)3.15
Book Value Per Share (mrq)0.70

Cash Flow Statement

Operating Cash Flow (ttm)-35.46M
Levered Free Cash Flow (ttm)-23.84M